Phase II study of pembrolizumab plus olaparib in the treatment of patients with advanced cholangiocarcinoma.
2020
TPS4659Background: Lack of an effective second-line treatment of patients (pts) with advanced cholangiocarcinoma (CC) necessitates the development of new therapies. Preclinical studies suggest CC s...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI